JPMorgan Chase & Co. Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $20.00

Travere Therapeutics (NASDAQ:TVTX) had its price objective boosted by JPMorgan Chase & Co. from $19.00 to $20.00 in a research note issued to investors on Tuesday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

TVTX has been the topic of a number of other reports. Canaccord Genuity Group boosted their price objective on shares of Travere Therapeutics from $15.00 to $18.00 and gave the company a buy rating in a research report on Tuesday, May 7th. Wedbush boosted their price objective on shares of Travere Therapeutics from $13.00 to $16.00 and gave the company an outperform rating in a research report on Friday, August 2nd. HC Wainwright boosted their price objective on shares of Travere Therapeutics from $19.00 to $20.00 and gave the company a buy rating in a research report on Monday, August 5th. Piper Sandler boosted their price objective on shares of Travere Therapeutics from $11.00 to $12.00 and gave the company a neutral rating in a research report on Friday, August 2nd. Finally, Barclays boosted their price objective on shares of Travere Therapeutics from $12.00 to $14.00 and gave the company an overweight rating in a research report on Friday, August 2nd. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Travere Therapeutics currently has an average rating of Moderate Buy and a consensus target price of $15.67.

Travere Therapeutics Stock Performance

Travere Therapeutics stock opened at $8.68 on Tuesday. The firm’s 50 day simple moving average is $8.65 and its 200-day simple moving average is $7.74. The company has a market cap of $663.93 million, a P/E ratio of -4.13 and a beta of 0.77. The company has a debt-to-equity ratio of 24.96, a current ratio of 3.04 and a quick ratio of 2.99. Travere Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $15.39.

Institutional Trading of Travere Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Parkman Healthcare Partners LLC raised its stake in Travere Therapeutics by 76.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,018,812 shares of the company’s stock valued at $9,159,000 after purchasing an additional 441,318 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Travere Therapeutics by 79.2% during the 1st quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company’s stock valued at $1,423,000 after purchasing an additional 81,611 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Travere Therapeutics during the 1st quarter valued at $452,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Travere Therapeutics during the 4th quarter valued at $5,711,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Travere Therapeutics during the 4th quarter valued at $137,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.